Eli Lilly Pre-Paid Expenses 2010-2024 | LLY

Eli Lilly pre-paid expenses from 2010 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
  • Eli Lilly pre-paid expenses for the quarter ending September 30, 2024 were $8.251B, a 57.22% increase year-over-year.
  • Eli Lilly pre-paid expenses for 2023 were $5.541B, a 88.03% increase from 2022.
  • Eli Lilly pre-paid expenses for 2022 were $2.947B, a 16.45% increase from 2021.
  • Eli Lilly pre-paid expenses for 2021 were $2.531B, a 11.87% decline from 2020.
Eli Lilly Annual Pre-Paid Expenses
(Millions of US $)
2023 $5,541
2022 $2,947
2021 $2,531
2020 $2,872
2019 $2,539
2018 $2,037
2017 $1,448
2016 $735
2015 $604
2014 $560
2013 $756
2012 $822
2011 $813
2010 $1,437
2009 $1,307
Eli Lilly Quarterly Pre-Paid Expenses
(Millions of US $)
2024-09-30 $8,251
2024-06-30 $7,138
2024-03-31 $6,349
2023-12-31 $5,541
2023-09-30 $5,248
2023-06-30 $4,532
2023-03-31 $3,575
2022-12-31 $2,947
2022-09-30 $2,742
2022-06-30 $2,807
2022-03-31 $2,698
2021-12-31 $2,531
2021-09-30 $3,051
2021-06-30 $3,297
2021-03-31 $3,234
2020-12-31 $2,872
2020-09-30 $3,209
2020-06-30 $3,105
2020-03-31 $2,762
2019-12-31 $2,539
2019-09-30 $2,370
2019-06-30 $2,316
2019-03-31 $2,227
2018-12-31 $2,037
2018-09-30 $1,879
2018-06-30 $1,689
2018-03-31 $1,570
2017-12-31 $1,448
2017-09-30 $1,064
2017-06-30 $1,010
2017-03-31 $822
2016-12-31 $735
2016-09-30 $757
2016-06-30 $790
2016-03-31 $792
2015-12-31 $604
2015-09-30 $762
2015-06-30 $730
2015-03-31 $797
2014-12-31 $560
2014-09-30 $822
2014-06-30 $1,086
2014-03-31 $1,112
2013-12-31 $756
2013-09-30 $853
2013-06-30 $989
2013-03-31 $988
2012-12-31 $822
2012-09-30 $790
2012-06-30 $953
2012-03-31 $1,323
2011-12-31 $813
2011-09-30 $1,178
2011-06-30 $1,304
2011-03-31 $1,691
2010-12-31 $1,437
2010-09-30 $1,192
2010-06-30 $1,128
2010-03-31 $1,018
2009-12-31 $1,307
2009-09-30 $1,006
2009-06-30 $825
2009-03-31 $652
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $789.394B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51